A Phase Ib/II Study of Ivosidenib with Venetoclax ? Azacitidine in IDH1-Mutated Myeloid Malignancies.
A Phase Ib/II Study of Ivosidenib with Venetoclax ? Azacitidine in IDH1-Mutated Myeloid Malignancies. Blood Cancer Discov. 2023 07 05; 4(4):276-293.